Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Activation of acetyl-CoA synthetase 2 mediates kidney injury in diabetic nephropathy
Jian Lu, Xue Qi Li, Pei Pei Chen, Jia Xiu Zhang, Liang Liu, Gui Hua Wang, Xiao Qi Liu, Ting Ting Jiang, Meng Ying Wang, Wen Tao Liu, Xiong Zhong Ruan, Kun Ling Ma
Jian Lu, Xue Qi Li, Pei Pei Chen, Jia Xiu Zhang, Liang Liu, Gui Hua Wang, Xiao Qi Liu, Ting Ting Jiang, Meng Ying Wang, Wen Tao Liu, Xiong Zhong Ruan, Kun Ling Ma
View: Text | PDF
Research Article Metabolism Nephrology

Activation of acetyl-CoA synthetase 2 mediates kidney injury in diabetic nephropathy

  • Text
  • PDF
Abstract

Albuminuria and podocyte injury are the key cellular events in the progression of diabetic nephropathy (DN). Acetyl-CoA synthetase 2 (ACSS2) is a nucleocytosolic enzyme responsible for the regulation of metabolic homeostasis in mammalian cells. This study aimed to investigate the possible roles of ACSS2 in kidney injury in DN. We constructed an ACSS2-deleted mouse model to investigate the role of ACSS2 in podocyte dysfunction and kidney injury in diabetic mouse models. In vitro, podocytes were chosen and transfected with ACSS2 siRNA and ACSS2 inhibitor and treated with high glucose. We found that ACSS2 expression was significantly elevated in the podocytes of patients with DN and diabetic mice. ACSS2 upregulation promoted phenotype transformation and inflammatory cytokine expression while inhibiting podocytes’ autophagy. Conversely, ACSS2 inhibition improved autophagy and alleviated podocyte injury. Furthermore, ACSS2 epigenetically activated raptor expression by histone H3K9 acetylation, promoting activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway. Pharmacological inhibition or genetic depletion of ACSS2 in the streptozotocin-induced diabetic mouse model greatly ameliorated kidney injury and podocyte dysfunction. To conclude, ACSS2 activation promoted podocyte injury in DN by raptor/mTORC1-mediated autophagy inhibition.

Authors

Jian Lu, Xue Qi Li, Pei Pei Chen, Jia Xiu Zhang, Liang Liu, Gui Hua Wang, Xiao Qi Liu, Ting Ting Jiang, Meng Ying Wang, Wen Tao Liu, Xiong Zhong Ruan, Kun Ling Ma

×

Figure 7

ACSS2 activation contributes to raptor transcriptional activation via H3K9ac in HG-treated podocytes.

Options: View larger image (or click on image) Download as PowerPoint
ACSS2 activation contributes to raptor transcriptional activation via H3...
(A and B) Western blotting analysis showing the effects of inhibition (A) or gene knockdown (B) of ACSS2 on H3K9ac levels in podocytes treated with HG (mean ± SD, *P < 0.05 vs. Ctrl or ***P < 0.001 vs. control; ##P < 0.01, ###P < 0.001 vs. HG; $$$P < 0.001 vs. control siRNA, n = 3 biological replicates, 1-way ANOVA). (C) Gene deletion of ACSS2 decreases the diabetes-induced upregulation of H3K9ac at raptor promoters in mouse kidneys (mean ± SD, ***P < 0.001 vs. Ctrl; ###P < 0.001 vs. DM, n = 3 biological replicates, 1-way ANOVA). (D) Chromatin immunoprecipitation (ChIP) analysis showing H3K9 acetylation levels in the promoters of raptor using antibodies to H3K9ac (mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 vs. Ctrl; #P < 0.05, ###P < 0.001 vs. HG, n = 3 biological replicates, 1-way ANOVA). (E) The reverse effects of OSS_128167 (a selective inhibitor that increases the acetylation of H3K9) to the transcriptional expression of raptor, which was inhibited by ACSS2 inhibitor on podocytes (mean ± SD, ***P < 0.001 vs. Ctrl; ###P < 0.001 vs. HG; $$P < 0.01 vs. HG, n = 3 biological replicates, 1-way ANOVA).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts